Microsatellite Instability and Immune Response: From Microenvironment Features to Therapeutic Actionability—Lessons from Colorectal Cancer

Microsatellite instability (MSI) can be found in 15–20% of all colorectal cancers (CRC) and is the key feature of a defective DNA mismatch repair (MMR) system. Currently, MSI has been established as a unique and pivotal biomarker in the diagnosis, prognosis, and treatment of CRC. MSI tumors display a strong lymphocytic activation and a shift toward a tumoral microenvironment restraining metastatic potential and ensuing in a high responsiveness to immunotherapy of MSI CRC. Indeed, neoplastic cells with an MMR defect overexpress several immune checkpoint proteins, such as programmed death-1 (PD-1) and programmed death-ligand 1(PD-L1), that can be pharmacologically targeted, allowing for the revival the cytotoxic immune response toward the tumor. This review aims to illustrate the role of MSI in the tumor biology of colorectal cancer, focusing on the immune interactions with the microenvironment and their therapeutic implications.

[1]  Aung Ko Win,et al.  Mortality by age, gene and gender in carriers of pathogenic mismatch repair gene variants receiving surveillance for early cancer diagnosis and treatment: a report from the prospective Lynch syndrome database , 2023, EClinicalMedicine.

[2]  P. Peltomäki,et al.  Lynch syndrome genetics and clinical implications. , 2023, Gastroenterology.

[3]  W. Grady,et al.  Emerging Tests for Noninvasive Colorectal Cancer Screening. , 2022, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[4]  A. Patnaik,et al.  A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer , 2022, ESMO open.

[5]  M. Gonen,et al.  PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer. , 2022, The New England journal of medicine.

[6]  H. Guadalajara,et al.  Update for Advance CAR-T Therapy in Solid Tumors, Clinical Application in Peritoneal Carcinomatosis From Colorectal Cancer and Future Prospects , 2022, Frontiers in Immunology.

[7]  R. Bellazzi,et al.  Tumor‐associated macrophages and risk of recurrence in stage III colorectal cancer , 2022, The Journal of Pathology: Clinical Research.

[8]  M. Sawyer,et al.  Nivolumab + low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  Mohamed Reda Keddar,et al.  A SIMPLI (Single-cell Identification from MultiPLexed Images) approach for spatially-resolved tissue phenotyping at single-cell resolution , 2021, Nature Communications.

[10]  F. Gaiani,et al.  Defects in MMR Genes as a Seminal Example of Personalized Medicine: From Diagnosis to Therapy , 2021, Journal of personalized medicine.

[11]  H. Liu,et al.  Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial. , 2021, The lancet. Gastroenterology & hepatology.

[12]  Hao Huang,et al.  Inhibitory immune checkpoints PDCD-1 and LAG-3 hypermethylation may reduce the risk of colorectal cancer , 2021, Molecular Medicine.

[13]  N. Wolmark,et al.  Use of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Initial Results From the Pembrolizumab Arm of a Phase 2 Randomized Clinical Trial. , 2021, JAMA oncology.

[14]  S. Rosso,et al.  Colorectal cancer incidence, mortality, and stage distribution in European countries in the colorectal cancer screening era: an international population-based study. , 2021, The Lancet. Oncology.

[15]  Ce Li,et al.  Comparative Analysis and in vitro Experiments of Signatures and Prognostic Value of Immune Checkpoint Genes in Colorectal Cancer , 2021, OncoTargets and therapy.

[16]  F. Gaiani,et al.  Heterogeneity of Colorectal Cancer Progression: Molecular Gas and Brakes , 2021, International journal of molecular sciences.

[17]  P. Pfeiffer,et al.  Complete pathological and serological response to immunotherapy in a patient with MMR-deficient early rectal cancer. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  J. Meyerhardt,et al.  Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. , 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

[19]  N. Wolmark,et al.  NRG-GI004/SWOG-S1610: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study—A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instabili , 2021, Journal of Clinical Oncology.

[20]  J. Galon,et al.  Gutting it Out: Developing Effective Immunotherapies for Patients With Colorectal Cancer. , 2021, Journal of immunotherapy.

[21]  N. Wolmark,et al.  Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  P. Gibbs,et al.  Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. , 2020, The New England journal of medicine.

[23]  M. Kloor,et al.  The shared frameshift mutation landscape of microsatellite-unstable cancers suggests immunoediting during tumor evolution , 2020, Nature Communications.

[24]  F. Marincola,et al.  Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Dan Huang,et al.  Somatic POLE exonuclease domain mutations elicit enhanced intratumoral immune responses in stage II colorectal cancer , 2020, Journal for ImmunoTherapy of Cancer.

[26]  L. Rénia,et al.  Granzyme B PET Imaging of Immune Checkpoint Inhibitor Combinations in Colon Cancer Phenotypes , 2020, Molecular Imaging and Biology.

[27]  M. Kloor,et al.  The “unnatural” history of colorectal cancer in Lynch syndrome: Lessons from colonoscopy surveillance , 2020, International journal of cancer.

[28]  R. Labianca,et al.  Localised Colon Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  P. Laurent-Puig,et al.  Corrigendum to 'Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study': Annals of Oncology 2020; Volume 31: 921-929. , 2020, Annals of Oncology.

[30]  M. Kloor,et al.  Implications of Hereditary Origin on the Immune Phenotype of Mismatch Repair-Deficient Cancers: Systematic Literature Review , 2020, Journal of clinical medicine.

[31]  A. Broeks,et al.  Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers , 2020, Nature Medicine.

[32]  C. Verschoor,et al.  Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer , 2020, Frontiers in Immunology.

[33]  M. Karin,et al.  Immunotherapy, Inflammation and Colorectal Cancer , 2020, Cells.

[34]  S. Barni,et al.  Microsatellite Instability and Survival in Stage II Colorectal Cancer: A Systematic Review and Meta-analysis , 2019, AntiCancer Research.

[35]  Guangzhe Zhao,et al.  Assessment of the expression of the immune checkpoint molecules PD‐1, CTLA4, TIM‐3 and LAG‐3 across different cancers in relation to treatment response, tumor‐infiltrating immune cells and survival , 2019, International journal of cancer.

[36]  A. Bardelli,et al.  Adaptive mutability of colorectal cancers in response to targeted therapies , 2019, Science.

[37]  V. Kuchroo,et al.  TIM3 comes of age as an inhibitory receptor , 2019, Nature Reviews Immunology.

[38]  Xin Zhou,et al.  Is microsatellite instability-high really a favorable prognostic factor for advanced colorectal cancer? A meta-analysis , 2019, World Journal of Surgical Oncology.

[39]  Song Liu,et al.  Tumor Infiltrating Lymphocytes and Macrophages Improve Survival in Microsatellite Unstable Colorectal Cancer , 2019, Scientific Reports.

[40]  N. Wolmark,et al.  Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[41]  M. Kloor,et al.  High endothelial venules are associated with microsatellite instability, hereditary background and immune evasion in colorectal cancer , 2019, British Journal of Cancer.

[42]  Aung Ko Win,et al.  Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database , 2019, Genetics in Medicine.

[43]  F. Ciardiello,et al.  Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy. , 2019, Cancer treatment reviews.

[44]  Z. Stadler,et al.  Immunotherapy in colorectal cancer: rationale, challenges and potential , 2019, Nature Reviews Gastroenterology & Hepatology.

[45]  V. Torri,et al.  Combined Low Densities of FoxP3+ and CD3+ Tumor-Infiltrating Lymphocytes Identify Stage II Colorectal Cancer at High Risk of Progression , 2019, Cancer Immunology Research.

[46]  C. Boland,et al.  EPCAM mutation update: Variants associated with congenital tufting enteropathy and Lynch syndrome , 2018, Human mutation.

[47]  M. Najafi,et al.  CD8+ cytotoxic T lymphocytes in cancer immunotherapy: A review , 2018, Journal of cellular physiology.

[48]  A. Bardelli,et al.  The Clinical Impact of the Genomic Landscape of Mismatch Repair-Deficient Cancers. , 2018, Cancer discovery.

[49]  G. Boland,et al.  The Effectiveness of Checkpoint Inhibitor Combinations and Administration Timing Can Be Measured by Granzyme B PET Imaging , 2018, Clinical Cancer Research.

[50]  F. Sinicrope.  Lynch Syndrome–Associated Colorectal Cancer , 2018, The New England journal of medicine.

[51]  Ping Chen,et al.  Comparison of immunological characteristics between paired mismatch repair-proficient and -deficient colorectal cancer patients , 2018, Journal of Translational Medicine.

[52]  F. Marincola,et al.  International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study , 2018, The Lancet.

[53]  F. Bertolini,et al.  Vinorelbine, cyclophosphamide and 5-FU effects on the circulating and intratumoural landscape of immune cells improve anti-PD-L1 efficacy in preclinical models of breast cancer and lymphoma , 2018, British Journal of Cancer.

[54]  M. Kloor,et al.  Complex pattern of immune evasion in MSI colorectal cancer , 2018, Oncoimmunology.

[55]  M. Sawyer,et al.  Nivolumab + ipilimumab combination in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): First report of the full cohort from CheckMate-142. , 2018 .

[56]  M. Kloor,et al.  High numbers of PDCD1 (PD-1)-positive T cells and B2M mutations in microsatellite-unstable colorectal cancer , 2018, Oncoimmunology.

[57]  M. Sawyer,et al.  Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  J. Albanell,et al.  403PPhase I studies of the novel carcinoembryonic antigen T-cell bispecific (CEA-CD3 TCB) antibody as a single agent and in combination with atezolizumab: Preliminary efficacy and safety in patients (pts) with metastatic colorectal cancer (mCRC) , 2017 .

[59]  J. Desai,et al.  Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. , 2017, The Lancet. Oncology.

[60]  Ludmila V. Danilova,et al.  Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade , 2017, Science.

[61]  A. Mantovani,et al.  Tumor-associated macrophages and response to 5-fluorouracil adjuvant therapy in stage III colorectal cancer , 2017, Oncoimmunology.

[62]  P. Møller,et al.  Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database , 2017, Gut.

[63]  E. Pilozzi,et al.  Exploring the Prognostic Role of Microsatellite Instability in Patients With Stage II Colorectal Cancer: A Systematic Review and Meta‐Analysis , 2017, Clinical colorectal cancer.

[64]  M. Canale,et al.  Immune Checkpoints as a Target for Colorectal Cancer Treatment , 2017, International journal of molecular sciences.

[65]  Daniel M. Corey,et al.  PD-1 expression by tumor-associated macrophages inhibits phagocytosis and tumor immunity , 2017, Nature.

[66]  K. Flaherty,et al.  Granzyme B PET Imaging as a Predictive Biomarker of Immunotherapy Response. , 2017, Cancer research.

[67]  I. Shapira,et al.  Immune checkpoint inhibitors in malignancies with mismatch repair deficiency: a review of the state of the current knowledge , 2017, Journal of Investigative Medicine.

[68]  W. Chua,et al.  The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy. , 2016, Clinical colorectal cancer.

[69]  E. Frangou,et al.  Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study. , 2016, The lancet. Gastroenterology & hepatology.

[70]  D. Sargent,et al.  Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  Christina Wu,et al.  Biomarkers for immune therapy in colorectal cancer: mismatch-repair deficiency and others. , 2016, Journal of gastrointestinal oncology.

[72]  J Ricke,et al.  ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[73]  F. Ciccarelli,et al.  Patients with genetically heterogeneous synchronous colorectal cancer carry rare damaging germline mutations in immune-related genes , 2016, Nature Communications.

[74]  D. Sargent,et al.  One good DNA-damage deserves another: Oxaliplatin in MSI-high colon cancer. , 2016, Journal of the National Cancer Institute.

[75]  J. Taïeb,et al.  Efficacy of Adjuvant Chemotherapy in Colon Cancer With Microsatellite Instability: A Large Multicenter AGEO Study. , 2016, Journal of the National Cancer Institute.

[76]  Mari Mino-Kenudson,et al.  PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes , 2016, Modern Pathology.

[77]  Z. Trajanoski,et al.  Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability. , 2016, Immunity.

[78]  K. Sheahan,et al.  Enrichment of Inflammatory IL-17 and TNF-α Secreting CD4+ T Cells within Colorectal Tumors despite the Presence of Elevated CD39+ T Regulatory Cells and Increased Expression of the Immune Checkpoint Molecule, PD-1 , 2016, Front. Oncol..

[79]  Jedd D. Wolchok,et al.  PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations , 2016, Science Translational Medicine.

[80]  M. Kloor,et al.  The Immune Biology of Microsatellite-Unstable Cancer. , 2016, Trends in cancer.

[81]  M. Kloor,et al.  Low density of FOXP3-positive T cells in normal colonic mucosa is related to the presence of beta2-microglobulin mutations in Lynch syndrome-associated colorectal cancer , 2016, Oncoimmunology.

[82]  C. Tournigand,et al.  Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[83]  R. Schreiber,et al.  The odds of immunotherapy success , 2015, Science.

[84]  J. Carethers,et al.  Genetics and Genetic Biomarkers in Sporadic Colorectal Cancer. , 2015, Gastroenterology.

[85]  J. Galon,et al.  Correlation between Density of CD8+ T-cell Infiltrate in Microsatellite Unstable Colorectal Cancers and Frameshift Mutations: A Rationale for Personalized Immunotherapy. , 2015, Cancer research.

[86]  E. Stoffel,et al.  Lynch syndrome and Lynch syndrome mimics: The growing complex landscape of hereditary colon cancer. , 2015, World journal of gastroenterology.

[87]  C. Yu,et al.  Defective Mismatch Repair Status was not Associated with DFS and OS in Stage II Colon Cancer Treated with Adjuvant Chemotherapy , 2015, Annals of Surgical Oncology.

[88]  L. Chow,et al.  The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment. , 2015, The oncologist.

[89]  Bert Vogelstein,et al.  PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. , 2015, The New England journal of medicine.

[90]  D. Chang,et al.  Lynch‐like syndrome: Characterization and comparison with EPCAM deletion carriers , 2015, International journal of cancer.

[91]  F. Ghiringhelli,et al.  Enhancing the anticancer effects of 5-fluorouracil: Current challenges and future perspectives , 2015, Biomedical journal.

[92]  Christopher D. Heinen,et al.  Milestones of Lynch syndrome: 1895–2015 , 2015, Nature Reviews Cancer.

[93]  J. Lang,et al.  Augmenting Antitumor Immune Responses with Epigenetic Modifying Agents , 2015, Front. Immunol..

[94]  F T Bosman,et al.  Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[95]  K. Kinzler,et al.  The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints , 2015, Journal of Immunotherapy for Cancer.

[96]  A. Voigt,et al.  Association of high CD4-positive T cell infiltration with mutations in HLA class II-regulatory genes in microsatellite-unstable colorectal cancer , 2015, Cancer Immunology, Immunotherapy.

[97]  W. Frankel,et al.  Colon and endometrial cancers with mismatch repair deficiency can arise from somatic, rather than germline, mutations. , 2014, Gastroenterology.

[98]  Daniel J Sargent,et al.  ACCENT-based web calculators to predict recurrence and overall survival in stage III colon cancer. , 2014, Journal of the National Cancer Institute.

[99]  J. Infante,et al.  Clinical Impact of Checkpoint Inhibitors as Novel Cancer Therapies , 2014, Drugs.

[100]  I. Nagtegaal,et al.  Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies , 2014, Clinical Cancer Research.

[101]  R. Labianca,et al.  Prognostic impact of deficient mismatch repair (dMMR) in 7,803 stage II/III colon cancer (CC) patients (pts): A pooled individual pt data analysis of 17 adjuvant trials in the ACCENT database. , 2014 .

[102]  A. Anderson.  Tim-3: An Emerging Target in the Cancer Immunotherapy Landscape , 2014, Cancer Immunology Research.

[103]  Gyeong Hoon Kang,et al.  Molecular and prognostic heterogeneity of microsatellite-unstable colorectal cancer. , 2014, World journal of gastroenterology.

[104]  I. Nagtegaal,et al.  Somatic mutations in MLH1 and MSH2 are a frequent cause of mismatch-repair deficiency in Lynch syndrome-like tumors. , 2014, Gastroenterology.

[105]  M. Toyota,et al.  Colorectal carcinomas with CpG island methylator phenotype 1 frequently contain mutations in chromatin regulators. , 2014, Gastroenterology.

[106]  A. Mantovani,et al.  Combined low-FOXP3+ and -CD3+tumor infiltrating lymphocytes: a signature of stage II MSS colorectal cancer at high-risk of recurrence , 2013, Journal of Immunotherapy for Cancer.

[107]  J. Lubiński,et al.  Germline deletions in the EPCAM gene as a cause of Lynch syndrome – literature review , 2013, Hereditary cancer in clinical practice.

[108]  Á. Carracedo,et al.  Risk of cancer in cases of suspected lynch syndrome without germline mutation. , 2013, Gastroenterology.

[109]  K. Kinzler,et al.  Cancer Genome Landscapes , 2013, Science.

[110]  J. Taube,et al.  Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody , 2012, Clinical Cancer Research.

[111]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of human colon and rectal cancer , 2012, Nature.

[112]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[113]  L. Laghi,et al.  Microsatellite Instability and Therapeutic Consequences in Colorectal Cancer , 2012, Digestive Diseases.

[114]  C. Capella,et al.  MSH3 Protein Expression and Nodal Status in MLH1-Deficient Colorectal Cancers , 2012, Clinical Cancer Research.

[115]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[116]  D. Kerr,et al.  Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[117]  R. Jover,et al.  EPCAM germ line deletions as causes of Lynch syndrome in Spanish patients. , 2010, The Journal of molecular diagnostics : JMD.

[118]  R. Labianca,et al.  Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[119]  Israel Lowy,et al.  Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[120]  Loise M. Francisco,et al.  The PD‐1 pathway in tolerance and autoimmunity , 2010, Immunological reviews.

[121]  M. Pino,et al.  The chromosomal instability pathway in colon cancer. , 2010, Gastroenterology.

[122]  B. Leggett,et al.  Role of the serrated pathway in colorectal cancer pathogenesis. , 2010, Gastroenterology.

[123]  Ajay Goel,et al.  Microsatellite instability in colorectal cancer. , 2010, Gastroenterology.

[124]  Zlatko Trajanoski,et al.  In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[125]  V. Torri,et al.  CD3+ cells at the invasive margin of deeply invading (pT3-T4) colorectal cancer and risk of post-surgical metastasis: a longitudinal study. , 2009, The Lancet. Oncology.

[126]  R. Wolff,et al.  Microsatellite instability and survival in rectal cancer , 2009, Cancer Causes & Control.

[127]  H. Hollema,et al.  Fas Ligand Expression in Lynch Syndrome-Associated Colorectal Tumours , 2008, Pathology & Oncology Research.

[128]  W. Grady,et al.  Genomic and epigenetic instability in colorectal cancer pathogenesis. , 2008, Gastroenterology.

[129]  Lieping Chen,et al.  Inhibitory B7-family molecules in the tumour microenvironment , 2008, Nature Reviews Immunology.

[130]  M. Kloor,et al.  Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers. , 2008, Gastroenterology.

[131]  V. Torri,et al.  Reduced Likelihood of Metastases in Patients with Microsatellite-Unstable Colorectal Cancer , 2007, Clinical Cancer Research.

[132]  Z. Trajanoski,et al.  Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.

[133]  P. Laird,et al.  CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer , 2006, Nature Genetics.

[134]  R. Houlston,et al.  Systematic review of microsatellite instability and colorectal cancer prognosis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[135]  Sudhir Srivastava,et al.  Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. , 2004, Journal of the National Cancer Institute.

[136]  H. Nagai,et al.  The correlation of microsatellite instability and tumor-infiltrating lymphocytes in hereditary non-polyposis colorectal cancer (HNPCC) and sporadic colorectal cancers: the significance of different types of lymphocyte infiltration. , 2004, Japanese journal of clinical oncology.

[137]  W. Gerald,et al.  Value of Histopathology in Predicting Microsatellite Instability in Hereditary Nonpolyposis Colorectal Cancer and Sporadic Colorectal Cancer , 2003, The American journal of surgical pathology.

[138]  Daniel J Sargent,et al.  Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. , 2003, The New England journal of medicine.

[139]  L. D. Tin,et al.  Microsatellite instability and high content of activated cytotoxic lymphocytes identify colon cancer patients with a favorable prognosis. , 2001, The American journal of pathology.

[140]  D. Pardoll,et al.  B7-Dc, a New Dendritic Cell Molecule with Potent Costimulatory Properties for T Cells , 2001, The Journal of experimental medicine.

[141]  G. Freeman,et al.  PD-L2 is a second ligand for PD-1 and inhibits T cell activation , 2001, Nature Immunology.

[142]  T. Okazaki,et al.  Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. , 2001, Science.

[143]  T. Honjo,et al.  Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. , 1999, Immunity.

[144]  A. Viel,et al.  High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability. , 1999, The American journal of pathology.

[145]  S Srivastava,et al.  A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. , 1998, Cancer research.

[146]  W. Bodmer,et al.  Selection for β2-microglobulin mutation in mismatch repair-defective colorectal carcinomas , 1996, Current Biology.

[147]  J. Allison,et al.  CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells , 1996, The Journal of experimental medicine.

[148]  L. Aaltonen,et al.  Better survival rates in patients with MLH1-associated hereditary colorectal cancer. , 1996, Gastroenterology.

[149]  B. Vogelstein,et al.  Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences. , 1994, The American journal of pathology.

[150]  Darryl Shibata,et al.  Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis , 1993, Nature.

[151]  S N Thibodeau,et al.  Microsatellite instability in cancer of the proximal colon. , 1993, Science.

[152]  J. Jass,et al.  A NEW PROGNOSTIC CLASSIFICATION OF RECTAL CANCER , 1987, The Lancet.